4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 5.3% – Should You Sell?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price traded down 5.3% during trading on Tuesday . The company traded as low as $10.53 and last traded at $10.4930. 523,751 shares traded hands during trading, a decline of 39% from the average session volume of 852,534 shares. The stock had previously closed at $11.08.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $17.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Barclays reduced their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Roth Capital lowered their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $28.70.

4D Molecular Therapeutics Stock Down 5.2%

The stock has a market capitalization of $600.15 million, a P/E ratio of -2.79 and a beta of 2.96. The business’s 50 day simple moving average is $10.43 and its two-hundred day simple moving average is $7.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.02) by $0.01. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. Analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 2,678 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the sale, the insider owned 3,594 shares of the company’s stock, valued at approximately $43,128. This represents a 42.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 10,763 shares of company stock worth $109,415 in the last quarter. Corporate insiders own 9.60% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds have recently bought and sold shares of FDMT. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $39,000. Wexford Capital LP bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth $41,000. Los Angeles Capital Management LLC purchased a new stake in 4D Molecular Therapeutics in the second quarter worth approximately $42,000. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics in the second quarter worth about $42,000. Finally, Farther Finance Advisors LLC grew its position in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after acquiring an additional 2,674 shares during the period. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.